Want to see BMRN full AI Analyst Report?

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

2,444 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BMRN Analyst Ratings

Strong Buy

15 Buy

5 Hold

0 Sell

Based on 20 analysts giving stock ratings to

BioMarin

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BMRN Stock 12 Month Forecast

Average Price Target

$86.58

▲(58.45% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $86.58 with a high forecast of $120.00 and a low forecast of $50.00. The average price target represents a 58.45% change from the last price of $54.64.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"49":"$49","67":"$67","85":"$85","103":"$103","121":"$121"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86.57894736842105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$86.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[49,67,85,103,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.82,62.60307692307693,67.38615384615385,72.16923076923077,76.9523076923077,81.73538461538462,86.51846153846154,91.30153846153846,96.08461538461538,100.8676923076923,105.65076923076923,110.43384615384616,115.21692307692308,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.82,60.03222672064777,62.24445344129555,64.45668016194332,66.66890688259109,68.88113360323887,71.09336032388664,73.3055870445344,75.51781376518218,77.73004048582996,79.94226720647774,82.15449392712551,84.36672064777328,{"y":86.57894736842105,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.82,57.21846153846154,56.61692307692308,56.01538461538462,55.41384615384615,54.81230769230769,54.21076923076923,53.60923076923077,53.00769230769231,52.40615384615385,51.80461538461539,51.20307692307692,50.60153846153846,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.09,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.74,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.03,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.82,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$86.58

Lowest Price Target$50.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Eric Joseph

Citi

$75→$76

Buy

39.09%

Upside

Reiterated

07/16/26

BioMarin price target raised to $76 from $75 at CitiBioMarin price target raised to $76 from $75 at Citi

Mitchell Kapoor

H.C. Wainwright

$50

Hold

-8.49%

Downside

Reiterated

07/14/26

Neutral Stance Maintained on BioMarin as Competitive Threats Offset VOXZOGO Progress; $50 Price Target Reaffirmed

Luca Issi

RBC Capital

$66→$62

Hold

13.47%

Upside

Reiterated

07/07/26

BioMarin price target lowered to $62 from $66 at RBC CapitalBioMarin price target lowered to $62 from $66 at RBC Capital

Akash Tewari

Jefferies

$104

Buy

90.34%

Upside

Reiterated

07/06/26

Jefferies Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$86

Buy

57.39%

Upside

Reiterated

06/03/26

BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim

Jason Gerberry

Bank of America Securities

$80

Buy

46.41%

Upside

Reiterated

05/29/26

Jason Gerberry Maintains Buy on BioMarin, Reiterates $80 Price Target Despite Voxzogo Patent Uncertainty

Paul Matteis

Stifel Nicolaus

$68

Hold

24.45%

Upside

Reiterated

05/24/26

BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus

Whitney Ijem

Canaccord Genuity

$116→$111

Buy

103.15%

Upside

Reiterated

05/22/26

BioMarin price target lowered to $111 from $116 at CanaccordBioMarin price target lowered to $111 from $116 at Canaccord

Christopher Raymond

Raymond James

―

Buy

―

Reiterated

05/22/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Allison Bratzel

Piper Sandler

$84→$82

Buy

50.07%

Upside

Reiterated

05/21/26

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Roivant Sciences (NASDAQ: ROIV)

Cory Kasimov

Evercore ISI

$120

Buy

119.62%

Upside

Reiterated

05/21/26

Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Mohit Bansal

Wells Fargo

$75

Buy

37.26%

Upside

Assigned

05/21/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Phil Nadeau

TD Cowen

$120

Buy

119.62%

Upside

Reiterated

05/21/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Eliana Merle

Barclays

$105

Buy

92.17%

Upside

Assigned

05/21/26

Analysts' Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)

Yun Zhong

Wedbush

$94

Buy

72.04%

Upside

Assigned

05/21/26

Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Eric Joseph

Citi

$75→$76

Buy

39.09%

Upside

Reiterated

07/16/26

BioMarin price target raised to $76 from $75 at CitiBioMarin price target raised to $76 from $75 at Citi

Mitchell Kapoor

H.C. Wainwright

$50

Hold

-8.49%

Downside

Reiterated

07/14/26

Neutral Stance Maintained on BioMarin as Competitive Threats Offset VOXZOGO Progress; $50 Price Target Reaffirmed

Luca Issi

RBC Capital

$66→$62

Hold

13.47%

Upside

Reiterated

07/07/26

BioMarin price target lowered to $62 from $66 at RBC CapitalBioMarin price target lowered to $62 from $66 at RBC Capital

Akash Tewari

Jefferies

$104

Buy

90.34%

Upside

Reiterated

07/06/26

Jefferies Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$86

Buy

57.39%

Upside

Reiterated

06/03/26

BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim

Jason Gerberry

Bank of America Securities

$80

Buy

46.41%

Upside

Reiterated

05/29/26

Jason Gerberry Maintains Buy on BioMarin, Reiterates $80 Price Target Despite Voxzogo Patent Uncertainty

Paul Matteis

Stifel Nicolaus

$68

Hold

24.45%

Upside

Reiterated

05/24/26

BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus

Whitney Ijem

Canaccord Genuity

$116→$111

Buy

103.15%

Upside

Reiterated

05/22/26

BioMarin price target lowered to $111 from $116 at CanaccordBioMarin price target lowered to $111 from $116 at Canaccord

Christopher Raymond

Raymond James

―

Buy

―

Reiterated

05/22/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Allison Bratzel

Piper Sandler

$84→$82

Buy

50.07%

Upside

Reiterated

05/21/26

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Roivant Sciences (NASDAQ: ROIV)

Cory Kasimov

Evercore ISI

$120

Buy

119.62%

Upside

Reiterated

05/21/26

Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Mohit Bansal

Wells Fargo

$75

Buy

37.26%

Upside

Assigned

05/21/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Phil Nadeau

TD Cowen

$120

Buy

119.62%

Upside

Reiterated

05/21/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Eliana Merle

Barclays

$105

Buy

92.17%

Upside

Assigned

05/21/26

Analysts' Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)

Yun Zhong

Wedbush

$94

Buy

72.04%

Upside

Assigned

05/21/26

Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AXGNAxoGen

NGNENeurogene

GHGuardant Health

ENOVEnovis

OCGNOcugen

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months

Akash TewariJefferies

Success Rate

13/31 ratings generated profit

Average Return

-2.64%

Copying Akash Tewari's trades and holding each position for 3 Months would result in 41.94% of your transactions generating a profit, with an average return of -2.64% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

21/43 ratings generated profit

Average Return

-3.26%

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 48.84% of your transactions generating a profit, with an average return of -3.26% per trade.

2 Years

Phil NadeauTD Cowen

Success Rate

12/26 ratings generated profit

Average Return

-4.97%

Copying Phil Nadeau's trades and holding each position for 2 Years would result in 46.15% of your transactions generating a profit, with an average return of -4.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMRN Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BMRN has received 31 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the past 3 months is 86.58.

Each month's total comprises the sum of three months' worth of ratings.

BMRN Financial Forecast

BMRN Earnings Forecast

Next quarter’s earnings estimate for BMRN is $0.95 with a range of $0.77 to $1.17. The previous quarter’s EPS was $0.76. BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Sales Forecast

Next quarter’s sales forecast for BMRN is $932.75M with a range of $887.00M to $980.00M. The previous quarter’s sales results were $778.62M. BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Stock Forecast FAQ

What is BMRN’s average 12-month price target, according to analysts?

Based on analyst ratings, Biomarin Pharmaceutical Inc.’s 12-month average price target is 86.58.

What is BMRN’s upside potential, based on the analysts’ average price target?

Biomarin Pharmaceutical Inc. has 58.45% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BMRN a Buy, Sell or Hold?

Biomarin Pharmaceutical Inc. has a consensus rating of Strong Buy which is based on 15 buy ratings, 5 hold ratings and 0 sell ratings.

What is Biomarin Pharmaceutical Inc.’s price target?

The average price target for Biomarin Pharmaceutical Inc. is 86.58. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $50.00. The average price target represents 58.45% Increase from the current price of $54.64.

What do analysts say about Biomarin Pharmaceutical Inc.?

Biomarin Pharmaceutical Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of BMRN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BMRN Analyst Ratings

BMRN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioMarin Pharmaceutical

BMRN Analyst Recommendation Trends

BMRN Financial Forecast

BMRN Earnings Forecast

BMRN Sales Forecast

BMRN Stock Forecast FAQ

Detailed List of Analyst Forecasts